Table 3.
Minimum inhibitory concentrations of amphotericin-B and 5-fluorocytosine for Cryptococcus neoformans and Cryptococcus gattii species complexes isolates from Latin America, according to the molecular type. Non-wild-type minimum inhibitory concentrations are underlined.
| Amphotericin-B (µg/mL) | 5-Fluorocytosine (µg/mL) | |||||
|---|---|---|---|---|---|---|
| MT | n | Range | GM | Range | GM | Ref. |
| VNI | 99 | 0.016–0.125 | 0.099 | 0.25–8 | 2.519 | [77] 1 |
| 26 | 0.03–0.25 | 0.060 | [79] 1 | |||
| 18 | 0.03–1 | - | 0.125–4 | - | [89] 1 | |
| 75 | 0.03–2 | 0.348 | [116] 1 | |||
| 19 | 0.125–0.25 | - | 0.5–8 | - | [17] 1 | |
| 7 | 0.125–0.25 | - | [65] 2 | |||
| 1 | 0.125 | - | [72] 2 | |||
| 17 | 0.5–1 | 0.670 | 0.5–8 | 2.770 | [58] 1 | |
| 1 | 0.5 | - | 2 | - | [91] 5 | |
| VNII | 2 | 0.12 | 0.120 | [116] 1 | ||
| VNIII | 4 | 0.06–0.5 | 0.173 | [116] 1 | ||
| VGI | 1 | 0.06 | - | 8 | - | [60] 1 |
| 4 | 0.125–0.5 | 0.290 | [54] 3 | |||
| 1 | 0.125 | - | 8 | - | [123] 1 | |
| 1 | 0.125 | - | 0.5 | - | [124] 1 | |
| VGII | 4 | 0.03–0.125 | 0.060 | [79] 1 | ||
| 7 | 0.03–0.25 | - | [90] 1 | |||
| 8 | 0.03–0.5 | 0.105 | 0.5–2 | 0.771 | [89] 1 | |
| 18 | 0.06–0.25 | 0.079 | 1–8 | 3.700 | [66] 1 | |
| 50 | 0.125–0.5 | 0.390 | [54] 3 | |||
| 2 | 0.125 | - | 2–4 | - | [81] 1 | |
| 1 | 0.19 | - | [65] 2 | |||
| 10 | 0.5–1 | 0.710 | 1–16 | 4.92 | [58] 1 | |
| 1 | 0.5 | - | 8 | - | [59] 1 | |
| VGIII | 54 | 0.125–2 | 0.030 | 0.5–8 | 2.095 | [32] 4 |
| 1 | 0.125 | - | 4 | - | [134] 1 | |
| 2 | 0.25 | - | [117] 3 | |||
Methodology to determine antifungal susceptibility: 1 M27-A3 guidelines of the Clinical and Laboratory Standards Institute (CLSI), 2 E-test strips, 3 European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (AFST-EUCAST) method E.Def.7.2., 4 Sensititre YeastOne plates, and 5 Vitek-2. MT: molecular type. n: number of studied isolates. GM: geometric mean.